Abstract
Global Drug Manufacturing Industry Outlook to 2010: Buyer Spend and
Procurement Strategies and the Impact of Recession and Recovery
Summary
“Global Drug Manufacturing Industry Outlook to 2010” is a new
report published by Global Markets Direct in association with ICD Research
that analyzes how drug manufacturing companies products & services spend,
procurement strategies & practices and business are being affected by the
recession. In an uncertain economic climate this report gives you access to
the category-level spending outlooks, buyer budgets, supplier selection
criteria, business challenges and investment opportunities of leading purchase
decision makers. The report also identifies buyers and suppliers future
growth, M&A and investment expectations. The research is based on an extensive
survey of senior and C-level industry executives from our market leading
panels.
Scope
- The opinions and forward looking statements of over 550 industry executives
have been captured in our in-depth survey, of which 65% represent Directors,
C-levels & Departmental Heads
- This report covers data and analysis on
buyer spend, procurement and industry developments by pharmaceutical process
and manufacturing, biopharma, biotech, public sector pharma, CRO and CMO
companies and leading suppliers worldwide
- The report examines current
practices and provides future expectations over the next 12-24 months
-
The research is based on primary survey research conducted by Global Markets
Direct in association with ICD Research accessing its B2B panels comprised of
senior purchase decision makers and leading supplier organizations
- Key
topics covered include buyer spend activity, procurement behaviors &
strategies and how these have been affected by the recession, threats &
opportunities for the drug manufacturing industry, economic outlook and
business confidence.
- In the report buyers identify what suppliers need
to do to maintain their business and the key actions being taken by industry
players to overcome the leading business threats
- The report provides
qualitative analysis of the key industry threats and opportunities and
contains full survey results
- The geographical scope of the research is
global – drawing on the activity and expectations of leading industry
players across the Americas, Europe, Asia-Pacific and Africa & Middle East
Highlights
- 40% of drug manufacturers expect to increase their procurement spend over
the next 12 months, a further 22% looking to maintain it at current levels,
however with many claiming to be re-evaluating their supplier base the market
open to competition is expected to increase over the coming year
- 38% of
buyers are seeking to engage in partnerships to optimize working capital and
reduce costs - closer cooperation between suppliers and buyers is being sought
during this time of market uncertainty
- Only 14% of drug manufacturers do
not regularly evaluate suppliers to ensure they meet high ethical and
environmental standards
Reasons to buy
- Drive revenues by understanding future product investment areas and growth
regions by leading industry players
- Formulate effective sales &
marketing strategies by identifying how buyer budgets are changing and where
spend will be directed to in the future
- Better promote your business by
aligning your capabilities and business practices with your customer’s
changing needs during these times of market uncertainty
- Secure stronger
customer relationships by understanding the leading business concerns and
changing strategies of buyers in the pharmaceutical industry
- Effectively
plan your business strategies
- Predict how the industry will grow,
consolidate and where it will stagnate
- Uncover the business outlook, key
challenges and opportunities identified by suppliers and buyers in the
industry
| 
View Cart
